Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Executive Summary

CDER Director Woodcock says it may not be necessary for the ANDA first-cycle approval rate to approach that for NDAs, but lowering the number of cycles to two would be desirable.


Related Content

Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
US FDA Wants To Predict ANDA Complete Response Responses
ANDA Approvals May Be Hindered By New Elemental Impurities Requirements
Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
No More 'Hidden' Facilities, US FDA Tells Generic Sponsors
More ANDAs To Be Eligible For Priority Review, Gottlieb Says
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts